StreetInsider.com News Articles

Form 6-K BetterLife Pharma Inc. For: Apr 30

Fri, 26 Jun 2026 15:00:00 -0400

si-local-file:///var/storage/secattach/20260626/26698090.html

Form 6-K BetterLife Pharma Inc. For: Apr 30

Fri, 26 Jun 2026 15:00:00 -0400

si-local-file:///var/storage/secattach/20260626/26698090.html

Form 6-K BetterLife Pharma Inc. For: Apr 30

Fri, 26 Jun 2026 15:00:00 -0400

si-local-file:///var/storage/secattach/20260626/26698090.html

Form 6-K BetterLife Pharma Inc. For: Jun 25

Thu, 25 Jun 2026 14:26:00 -0400

si-local-file:///var/storage/secattach/20260625/26691485.html

Form 6-K BetterLife Pharma Inc. For: Jun 25

Thu, 25 Jun 2026 14:26:00 -0400

si-local-file:///var/storage/secattach/20260625/26691485.html

Form 6-K BetterLife Pharma Inc. For: Jun 25

Thu, 25 Jun 2026 14:26:00 -0400

si-local-file:///var/storage/secattach/20260625/26691485.html

BetterLife Pharma hires Syner-G for GMP manufacturing of BETR-001

Thu, 25 Jun 2026 08:02:26 -0400

BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) has entered into an agreement with Syner-G BioPharma Group to oversee good manufacturing practice (GMP) production of its lead drug candidate, BETR-001, as part of the company's planned investigational new drug (IND) application and Phase 1 clinical program, according to a press release.

BETR-001 is 2-bromo-lysergic acid diethylamide (2-Br-LSD), described by the company as a non-hallucinogenic derivative of LSD. The compound targets neuroreceptors associated with migraines, cluster headaches, depression, and anxiety. BetterLife states BETR-001 is completing final IND-enabling studies, with an IND filing and Phase 1 trial start projected for the first

BetterLife Engages Syner-G to Oversee GMP Manufacturing of BETR-001 for IND and Phase 1

Thu, 25 Jun 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - June 25, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") announces it has entered into an agreement with Syner-G BioPharma Group ("Syner-G") to oversee GMP manufacturing of BETR-001 for its planned IND and Phase 1 program.

BETR-001 is 2-bromo-lysergic acid diethylamide (2-Br-LSD), a non-hallucinogenic derivative of LSD. BETR-001 is active against neuroreceptors involved in migraines and cluster headaches, as well as neuroreceptors involved in psychiatric disorders such as depression and anxiety. While it is a potent neuroplastogen and an agonist of the 5-HT2A, 5-HT1B, 5-HT1D, and 5-HT1F receptors, BETR-001 is designed to

BetterLife Engages Syner-G to Oversee GMP Manufacturing of BETR-001 for IND and Phase 1

Thu, 25 Jun 2026 08:00:00 -0400

BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing

Mon, 22 Jun 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - June 22, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") today announced it has closed a CAD $2,000,000 convertible debenture financing ("Debenture" or "Financing"). The Debenture will fund the remaining IND-enabling work on the Company's lead candidate, BETR-001, as BetterLife sharpens its focus on neurological pain indications, with an initial emphasis on cluster headache and migraine.

The Financing is the first capital deployed since the Company appointed Doug Drysdale as Executive Chairman and Director on May 13, 2026. Mr. Drysdale, formerly CEO of Cybin Inc., led that company from molecule inception to Phase

BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing

Mon, 22 Jun 2026 08:00:00 -0400

Form 20-F BetterLife Pharma Inc. For: Jan 31

Mon, 01 Jun 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260601/26584076.html

Form 20-F BetterLife Pharma Inc. For: Jan 31

Mon, 01 Jun 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260601/26584076.html

Form 20-F BetterLife Pharma Inc. For: Jan 31

Mon, 01 Jun 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260601/26584076.html

BetterLife Pharma names Doug Drysdale as Executive Chairman

Wed, 13 May 2026 08:05:45 -0400

BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) announced the appointment of Doug Drysdale as Executive Chairman and Director. Drysdale previously served as CEO of Cybin Inc. (NYSE: CYBN) and has been working as a corporate advisor for BetterLife.

During his tenure at Cybin, Drysdale led the company from molecule inception to Phase 3 trials over three years. The company granted Drysdale stock options to purchase 3,500,000 common shares at an exercise price of $0.065, with monthly vesting over 24 months and a 10-year term.

"We are delighted to welcome Doug to our Board of Directors. His proven global leadership, underscored

BetterLife Pharma names Doug Drysdale as Executive Chairman

Wed, 13 May 2026 08:05:45 -0400

"We are delighted to welcome Doug to our Board of Directors. His proven global leadership, underscored

BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director

Wed, 13 May 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - May 13, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotech company, is pleased to announce it has appointed Doug Drysdale, currently BetterLife's corporate advisor and formerly CEO of Cybin Inc. ("Cybin") (NYSE: CYBN), as Executive Chairman and Director.

At Cybin, Mr. Drysdale led the company's strategy and team build-out, taking it from molecule inception to Phase 3 trials in just three years. Mr. Drysdale is known as a vocal advocate for revolutionizing mental healthcare through numerous speaking engagements, panel participations, and media interviews.

"We are delighted

BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director

Wed, 13 May 2026 08:00:00 -0400

"We are delighted

BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director

Wed, 13 May 2026 08:00:00 -0400

"We are delighted

BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director

Wed, 13 May 2026 08:00:00 -0400

"We are delighted

Form 6-K BetterLife Pharma Inc. For: Apr 13

Mon, 13 Apr 2026 14:00:00 -0400

si-local-file:///var/storage/secattach/20260413/26305082.html

Form 6-K BetterLife Pharma Inc. For: Apr 13

Mon, 13 Apr 2026 14:00:00 -0400

si-local-file:///var/storage/secattach/20260413/26305082.html

Form 6-K BetterLife Pharma Inc. For: Apr 13

Mon, 13 Apr 2026 14:00:00 -0400

si-local-file:///var/storage/secattach/20260413/26305082.html

BetterLife Pharma to Participate in YAFO Capital Access Asia Partnering Forum During JPM Week in San Francisco

Tue, 06 Jan 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - January 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biopharmaceutical company focused on development of BETR-001, its proprietary non-hallucinogenic derivative of lysergic acid diethylamide ("LSD") for the treatment of neurological disorders, today announced that it will be participating in the YAFO Capital Access Asia 2025 Partnering Forum, held in San Francisco, California, during JPM Week.

The YAFO Capital Access Asia Partnering Forum brings together innovative life science companies and leading investors, pharmaceutical partners, and strategic advisors, with a particular focus on fostering collaboration between North American and Asian capital

BetterLife Pharma to Participate in YAFO Capital Access Asia Partnering Forum During JPM Week in San Francisco

Tue, 06 Jan 2026 08:00:00 -0400